This work has shown that the blood-brain barrier provides the platform for CNS drug delivery programs, which should be developed in parallel with traditional CNS drug discovery efforts in the molecular neurosciences.Expand
Brain drug development programs of the future need to be re-configured so that drugs are formulated to enable transport into the brain via endogenous BBB transporters.Expand
The functions of the various known transport systems in the brain are reviewed and how the development of BBB drug-targeting programs in pharmaceutical and academic settings may lead to more efficacious treatments are discussed.Expand
The classical physiologic techniques may now be correlated with modern biochemical and molecular biological approaches using freshly isolated animal or human brain capillaries to form an 'in vitro BBB' model.Expand
Specific OX26-mediated targeting of daunomycin to the rat brain was achieved by the use of an immunoliposome-based drug delivery system and determination of brain levels of immunolIPosomes over 24 h revealed that immunolipsomes accumulate in brain tissue.Expand
It is important to merge CNS drug discovery and CNS drug delivery as early as possible in the overall CNS drug development process to avoid termination caused by negligible blood‐brain barrier transport.Expand
Molecular Trojan Horses, such as endogenous peptides, modified proteins or peptidomimetic monoclonal antibodies, are one way of tricking the brain into allowing these molecules to pass.Expand
The recent demonstration of in vivo pharmacologic effects in brain following the systemic administration of relatively low doses (12 microg/kg) of neuropeptide is demonstrated.Expand
Findings indicate the neurotoxicity of hyperphenylalninemia is not restricted to the phenylketonuria range of approximately 2000 μM, but is exerted in the supra-physiological range of 200–500 μM.Expand